Table 1.
Propensity-score matched pairs of patients treated using resin versus glass 90Y microspheres.
| Characteristic | Resin (57 patients) |
Glass (57 patients) |
p |
|---|---|---|---|
| Age | 61 ± 12 | 61 ± 12 | 0.88 |
| Female | 36 (63%) | 39 (68%) | 0.69 |
| Pathology | 0.99 | ||
| HCC | 1 (2%) | 1 (2%) | |
| Cholangiocarcinoma | 2 (4%) | 1 (2%) | |
| Colorectal | 22 (39%) | 23 (40%) | |
| NET, grade 1 | 1 (2%) | 2 (4%) | |
| NET, grade 2 | 3 (5%) | 3 (5%) | |
| NET, grade 3 | 2 (4%) | 1 (2%) | |
| Breast | 14 (25%) | 16 (28%) | |
| Sarcoma | 1 (2%) | 1 (2%) | |
| Other | 11 (19%) | 9 (16%) | |
| Liver function | |||
| Child-Pugh score | 0.24 | ||
| A5 | 41 (72%) | 43 (75%) | |
| A6 | 15 (26%) | 10 (18%) | |
| B7 | 1 (2%) | 4 (7%) | |
| Albumin | 3.88 ± 0.45 | 3.79 ± 0.42 | 0.29 |
| Bilirubin | 0.71 ± 0.50 | 0.64 ± 0.29 | 0.40 |
| Tumor burden | |||
| % tumor volume in treated liver | 22% ± 26% | 18% ± 16% | 0.36 |
| Extrahepatic disease | 39 (68%) | 38 (67%) | 1.0 |
| CEA (for colorectal) | 520 ± 1100 | 870 ± 2400 | 0.53 |
| Prior chemotherapy | 48 (84%) | 47 (82%) | 1.0 |
| Lung shunt fraction | 5.1% ± 3.7% | 4.8% ± 3.3% | 0.68 |
| Treatment volume (cm3) | 1200 ± 600 | 1100 ± 500 | 0.17 |
| T:N ratio (MAA scan) | 3.0 ± 3.2 | 3.6 ± 3.7 | 0.31 |